Cellectar Biosciences, Inc. (CLRB) stock
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.01−0.13 (-11.40%)
Close on Nov 16, 2026Market cap $9.55MP/E –Yield –
Cellectar Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cellectar Biosciences's ebitda for the twelve months ending Dec 31, 2025 was -$22.77M. For fiscal 2025 it was -$22.77M. The highest annual figure on record is -$3.61M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.77M | – |
| FY2024 | Dec 31, 2024 | -$51.49M | – |
| FY2023 | Dec 31, 2023 | -$38.77M | – |
| FY2022 | Dec 31, 2022 | -$28.67M | – |
| FY2021 | Dec 31, 2021 | -$23.98M | – |
| FY2020 | Dec 31, 2020 | -$15.15M | – |
| FY2019 | Dec 31, 2019 | -$14.05M | – |
| FY2018 | Dec 31, 2018 | -$13.25M | – |
| FY2017 | Dec 31, 2017 | -$12.05M | – |
| FY2016 | Dec 31, 2016 | -$9.09M | – |
| FY2015 | Dec 31, 2015 | -$8.40M | – |
| FY2014 | Dec 31, 2014 | -$9.52M | – |
| FY2013 | Dec 31, 2013 | -$11.98M | – |
| FY2012 | Dec 31, 2012 | -$8.26M | – |
| FY2011 | Dec 31, 2011 | -$6.45M | – |
| FY2010 | Dec 31, 2010 | -$3.61M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$5.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.66M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.38M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.10M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.78M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.60M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.07M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.89M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.44M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.12M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.73M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.56M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.38M | – |
See a number that looks wrong?